Samyang Biopharm announced that the results of its non-clinical research on the messenger RNA (mRNA) cancer vaccine delivery system, 'NanoReady,' have been published in an international journal.
The company revealed on August 20 that a research paper on NanoReady, one of its proprietary gene delivery platforms called 'SENS (Selectivity Enabling Nano Shell),' was featured in the 'Journal of Controlled Release,' a leading journal in the field of drug delivery and formulation technology.
The paper is titled 'NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity.' It was selected as a cover article due to its originality and academic value.
NanoReady is a nanoparticle-based gene delivery system created by combining lipids and biodegradable polymers developed by Samyang Biopharm. It is characterized by its ability to selectively deliver mRNA to dendritic cells in the spleen, which are responsible for immune function.
Notably, the delivery system can be manufactured and stored separately from the mRNA. Once mRNA containing antigen information tailored to individual cancer characteristics is prepared, it can be mixed with NanoReady to produce a personalized mRNA cancer vaccine.
According to Samyang Biopharm, unlike conventional lipid nanoparticles (LNPs) widely used for mRNA delivery, NanoReady is designed with a multilayer structure. It can carry approximately 20 times more mRNA per particle than LNPs, thereby inducing a stronger immune response from T cells that attack cancer cells.
The safety of repeated administration is also highlighted as a key differentiator. Samyang Biopharm explained that PEG-lipids and PC series auxiliary lipids used in LNPs may promote the removal of particles from the body during repeated administration or cause hypersensitivity reactions depending on dosage and administration methods.
In contrast, NanoReady is designed to be suitable for repeated administration by optimizing its composition without using PEG-lipids and PC series auxiliary lipids. Since cancer vaccines may require multiple doses during treatment, the safety of repeated administration is a crucial factor.
In non-human primate (NHP) experiments, the administration of NanoReady loaded with cancer antigen mRNA showed that the delivery system selectively transported the antigen mRNA to spleen cells and induced T cell immune responses against the cancer antigen. Comprehensive evaluations, including blood and tissue tests after repeated administration, did not reveal any systemic toxicity.
Samyang Biopharm plans to continue publishing research results on SENS-based delivery systems that can be applied to preventive vaccines and treatments for liver and lung diseases.
Additionally, the company aims to explore next-generation therapeutic pipelines utilizing the SENS platform for in vivo CAR-T therapies, central nervous system (CNS) targeted therapies, and new RNA cargo areas.
A representative from Samyang Biopharm stated, 'The results of this research support that NanoReady is a platform that can be applied to various mRNA candidates beyond a research-stage delivery system. We will focus on expanding platform-based business through the follow-up development of our own mRNA cancer vaccine pipeline, as well as global technology transfers and joint drug development.'
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.